Le Lézard
Classified in: Science and technology, Business
Subjects: PDT, DIS

The American private investment fund XY Booster enhances neurodivergent talent


The corporation, which provides funding to socially impactful startups incubated in Spanish-speaking markets scalable at an international level, is betting on expanding neurodiversity in companies as an intelligent investment with tangible benefits. XY Booster, with offices in New York, San Francisco, Mexico and Barcelona (Spain), has 40% neurodivergent talent in its workforce.

NEW YORK, May 7, 2024 /PRNewswire/ -- Between 15 and 20% of the world's population is neurodivergent, according to Stanford University's Neurodiversity at Work program. This percentage reveals that at least one in every six people has conditions such as dyslexia, attention deficit hyperactivity disorder (ADHD), Tourette syndrome, dyspraxia and dyscalculia or belongs to the autism spectrum.

Neurodivergent individuals share commonalities in how they learn and process information, which can bring significant value in the workplace. Among other differential skills, individuals with dyslexia excel in attention to detail, those on the autism spectrum have up to 50% greater ability to recognize patterns, and individuals with ADHD exhibit innovative thinking, highly skilled in creatively solving problems.

However, neurodiverse individuals who disclose their condition often face difficulties in obtaining employment, mainly due to organizations' unawareness about what neurodivergence entails.

Therefore, more and more experts emphasize that forming a neurodiverse workforce not only promotes inclusion but is also a strategic move with significant financial and social benefits. In fact, a report by consulting firm Deloitte states that teams with neurodivergent professionals can be 30% more productive.

According to Mark Long, Chief Marketing Officer of the startup XtraordinarY, focused on enhancing neurodivergent talent and backed by the American private investment fund XY Booster, "creating an environment favorable to neurodiversity and investing in it is beneficial for everyone. It strengthens the company by fostering innovation, boosting productivity, and expanding its talent pool. It also allows organizations to contribute to a more inclusive society and potentially benefit from tax incentives."

Both Mark Long and Robert Monturiol, founder and president of XY Booster, are dyslexic, so their commitment to promoting the inclusion of neurodiverse individuals in their projects is paramount.

"By embracing neurodiversity in the team and in its investment practices, XY Booster can unlock new opportunities, improve decision-making processes, and increase its overall effectiveness as a fund. Thus, it can gain a competitive advantage in the market and, at the same time, have a positive impact on society," emphasizes Long.

Logo: https://mma.prnewswire.com/media/2406512/XY_Booster.jpg

SOURCE XY Booster


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: